All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
BMT Tandem Meetings | Ommited doses of post-transplant MTX with alternative agents as GvHD prophylaxis – a retrospective study
Andrew Lin and colleagues from Memorial Sloan Kettering Cancer Center, New York, NY, conducted a retrospective analysis of outcomes in patients who had varied quantities of mini-methotrexate (MTX) doses with a calcineurin inhibitors (CNI) following allogeneic transplant. The results were presented on February 21 at the 2018 BMT Tandem Meetings in Salt Lake City, UT.
The full dosing schedule for mini-MTX, graft-versus-host disease (GvHD) prophylaxis, is 4 doses given intravenously. This analysis reviewed GvHD and survival results for patients based on receipt of 1-3 or all 4 doses of MTX after transplant. In cases when fewer than 4 doses were given, alternate prophylaxis agents, such as corticosteroids or MMF were added to therapy.
Patients:
- N = 198 total patients
- Omitted dose group = 35, median age = 48.9 years
- Full dose group = 163, median age = 55.3 years
Key findings:
- Reasons for dose omission: mucositis, hyperbilirubinemia, pleural effusions
- Results at 36 months
- Non-relapse mortality: omitted dose =36.4% vs full dose = 16.6%, P = 0.008
- GvHD-free mortality: omitted dose = 20.6% vs full dose = 12.8%, P = 0.220
- cGvHD: omitted dose = 15.7% vs full dose = 30.6%, P = 0.096
- Overall survival: omitted dose = 37.4% vs full dose = 53.8%, P = 0.008
- Relapse -free survival: omitted dose = 29.6% vs8%, P = 0.046
The findings of this study demonstrated that skipping doses of mini-MTX did not impact incidence of cGVHD, but relapse prior to cGVHD development was considered a competing risk and it led to adverse survival outcomes. Administering an alternative agent, MMF or corticosteroids may improve the increased risk of aGvHD.Key limitation of this study was the small number of patients receiving omitted doses of MTX.
Given the expectation of poor survival outcomes when methotrexate is omitted, it is crucial for medical teams to provide sufficient supportive care of toxicities, which will allow patients to receive a full four-dose schedule.
References